At a glance
- Originator Eisai Co Ltd
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Nov 1995 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 10 Feb 1995 Preclinical development for Cancer in Japan (Unknown route)